Carbimazole is a methimazole prodrug that is clinically used to treat hyperthyroidism and Graves’ disease; it exhibits immunomodulatory and anti-thyroid activities. Carbimazole inhibits thyroid peroxidase, decreasing production of thyroid hormones T3 and T4. In clinical subjects with Graves’ disease, carbimazole increases levels of IL-2 and free radical scavengers and decreases levels of IL-2Rs.
| Cas No. | 22232-54-8 |
|---|---|
| Purity | ≥98% |
| Formula | C7H10N2O2S |
| Formula Wt. | 186.23 |
| Chemical Name | 2,3-Dihydro-3-methyl-2-thioxo-1H-imidazole-1- carboxylic acid ethyl ester |
| IUPAC Name | ethyl 3-methyl-2-sulfanylideneimidazole-1-carboxylate |
| Synonym | Athyromazole; Neo-mercazole; Neo-Thyreostat |
| Melting Point | 122-125°C |
| Solubility | Soluble in water (500parts), ethanol (50parts), and chloroform (3parts). |
| Appearance | White-almost white crystalline powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | C0172 Info Sheet PDF |
|---|
Manna D, Roy G, Mugesh G. Antithyroid drugs and their analogues: synthesis, structure, and mechanism of action. Acc Chem Res. 2013 Nov 19;46(11):2706-15. PMID: 23883148.
Wilson R, McKillop JH, Buchanan LM, et al. The effect of carbimazole therapy on interleukin 2, interleukin 2 receptors and free radicals. Autoimmunity. 1990;8(1):3-7. PMID: 2129783.
